

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Pillar Invest Corp</u>  (Last) (First) (Middle) PILLAR INVEST OFFSHORE SAL STARCO CTR, BLOC B, 3RD FLOOR, OMAR DAOUK STREET  (Street) BEIRUT M8 2020-3313  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>IDERA PHARMACEUTICALS, INC. [ IDRA ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 05/12/2020	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Common Warrants	(1)(2)	05/12/2020 <sup>(1)(2)</sup>		P		3,039,514		(1)(2)	(1)(2)	Common Stock	3,039,514	(1)(2)	3,039,514	I	By Pillar Partners Foundation, L.P. See Footnote <sup>(3)</sup>

1. Name and Address of Reporting Person\*  
Pillar Invest Corp  
  
 (Last) (First) (Middle)  
 PILLAR INVEST OFFSHORE SAL STARCO CTR,  
 BLOC B, 3RD FLOOR, OMAR DAOUK STREET  
  
 (Street)  
 BEIRUT M8 2020-3313  
  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Pillar Partners Foundation, L.P.  
  
 (Last) (First) (Middle)  
 PILLAR INVEST OFFSHORE SAL STARCO CTR,  
 BLOC B, 3RD FLOOR, OMAR DAOUK STREET  
  
 (Street)  
 BEIRUT M8 2020-3313  
  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Umari Abude  
  
 (Last) (First) (Middle)  
 PILLAR INVEST OFFSHORE SAL STARCO CTR,  
 BLOC B, 3RD FLOOR, OMAR DAOUK STREET  
  
 (Street)  
 BEIRUT M8 2020-3313  
  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*

ZEIN YOUSSEF EL

(Last) (First) (Middle)  
PILLAR INVEST OFFSHORE SAL STARCO CTR,  
BLOC B, 3RD FLOOR, OMAR DAOUK STREET

(Street)  
BEIRUT M8 2020-3313

(City) (State) (Zip)

**Explanation of Responses:**

1. On April 7, 2020, upon the consummation of a private placement of the Issuer, Pillar Partners Foundation, L.P. ("Pillar Foundation"), acquired, in the Private Placement, 3,039,514 shares of common stock (the "Pillar Foundation Shares") as well as warrants to purchase 3,039,514 shares of common stock of the Issuer (the "Pillar Foundation Warrants"). Each Pillar Foundation Share and the associated Pillar Foundation Warrant had a combined purchase price of \$1.645, which combined purchase price included \$0.125 for each share of common stock underlying each Pillar Foundation Warrant. The exercise price of each Pillar Foundation Warrant is \$2.28 per share, subject to adjustment pursuant to the terms of the Pillar Foundation Warrants and the Pillar Foundation Warrants expire 3 years from their issuance date.
2. The Pillar Foundation Warrants became exercisable on May 12, 2020 following receipt of shareholder approval for the sufficient increase in the Issuer's authorized shares of common stock to cover the exercise of the Pillar Foundation Warrants. The Pillar Foundation Warrants are exercisable, to the extent that after giving effect to such exercise the holders thereof and their affiliates would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer.
3. Pillar Invest Corporation ("Pillar GP") is the general partner of Pillar Pharmaceuticals I, L.P., Pillar Pharmaceuticals II, L.P., Pillar Pharmaceuticals III, L.P., Pillar Pharmaceuticals IV, L.P., Pillar Pharmaceuticals V, L.P., Pillar Pharmaceuticals 6, L.P. and Pillar Foundation (collectively, the "Pillar Funds"). Youssef El Zein and Abude Umari are directors of Pillar GP. Each of Pillar GP, Mr. El Zein and Mr. Umari disclaims Section 16 beneficial ownership of the securities beneficially owned by the Pillar Funds and this report shall not be deemed an admission that any of Pillar GP, Mr. El Zein or Mr. Umari is the Section 16 beneficial owner of any such securities, except to the extent of its or his pecuniary interest therein, if any, by virtue of its or his ownership interest in the Pillar Funds or Pillar GP, as applicable.

**Remarks:**

Pillar Invest Corporation, /s/  
Youssef El Zein, Authorized 09/04/2020  
Person

Pillar Partners Foundation, L.P.,  
/s/ Youssef El Zein, Authorized 09/04/2020  
Person

/s/ Abude Umari 09/04/2020

/s/ Youssef El Zein 09/04/2020

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.